NCT06993038 Adenosine vs Diltiazem for Treatment of SVT in the ED
| NCT ID | NCT06993038 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Anne E. Zepeski |
| Condition | Supraventricular Tachycardia (SVT) |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-08-01 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 20 participants in total. It began in 2025-08-01 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.
Eligibility Criteria
Inclusion Criteria: 1. Adult patients (18 years and older) 2. Diagnosis of acute, stable SVT in the emergency department Exclusion Criteria: 1. Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting). 2. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome 3. History of heart failure with reduce ejection fraction (HFrEF) (LVEF\</= 40%) 4. Severe bronchoconstrictive lung disease 5. Prior hypersensitivity to study medication 6. Previously enrolled in pilot study 7. Pregnant 8. Incarcerated
Contact & Investigator
Anne Zepeski, PharmD
PRINCIPAL INVESTIGATOR
University of Iowa
Frequently Asked Questions
Who can join the NCT06993038 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Supraventricular Tachycardia (SVT). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06993038 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06993038 currently recruiting?
Yes, NCT06993038 is actively recruiting participants. Contact the research team at anne-zepeski@uiowa.edu for enrollment information.
Where is the NCT06993038 trial being conducted?
This trial is being conducted at Iowa City, United States.
Who is sponsoring the NCT06993038 clinical trial?
NCT06993038 is sponsored by Anne E. Zepeski. The principal investigator is Anne Zepeski, PharmD at University of Iowa. The trial plans to enroll 20 participants.